This content is in French.
Reprogramming the immune system: a new strategy against ovarian cancer
16 mars 2026
By Elodie Vaz | Published on March 16, 2026 | 3 min read
Ovarian cancer remains one of the most feared gynecological cancers, largely due to late diagnosis and a strong tendency to develop therapeutic resistance. The most common and aggressive form is high-grade serous ovarian cancer, which often responds initially to chemotherapy but frequently becomes refractory to treatment over time.
While immunotherapies, particularly immune checkpoint inhibitors, have transformed the management of several solid tumors, their effectiveness in ovarian cancer has been limited.
Ovarian cancer remains one of the most feared gynecological cancers, largely due to late diagnosis and a strong tendency to develop therapeutic resistance. The most common and aggressive form is high-grade serous ovarian cancer, which often responds initially to chemotherapy but frequently becomes refractory to treatment over time.
While immunotherapies, particularly immune checkpoint inhibitors, have transformed the management of several solid tumors, their effectiveness in ovarian cancer has been limited.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
View the source
